Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
Selling, General & Administrative
Altamira Therapeutics Ltd
Selling, General & Administrative Peer Comparison
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
Selling, General & Administrative
-CHf3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Novartis AG
SIX:NOVN
|
Selling, General & Administrative
-$15.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
0%
|
|
Roche Holding AG
SIX:ROG
|
Selling, General & Administrative
-CHf13.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Selling, General & Administrative
-$2.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Altamira Therapeutics Ltd's Selling, General & Administrative?
Selling, General & Administrative
-3m
CHF
Based on the financial report for Dec 31, 2023, Altamira Therapeutics Ltd's Selling, General & Administrative amounts to -3m CHF.
What is Altamira Therapeutics Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
6%
Over the last year, the Selling, General & Administrative growth was 50%. The average annual Selling, General & Administrative growth rates for Altamira Therapeutics Ltd have been -5% over the past three years , 6% over the past five years .